What is denosumab?
Denosumab is a laboratory-produced monoclonal antibody that blocks RANK ligand, a signal needed for the formation and activity of osteoclasts—the cells that break down bone. For osteoporosis, the established regimen is 60 mg injected under the skin by a healthcare professional every six months.
Denosumab is also used in a different dose and schedule for certain cancer-related bone conditions. Those regimens and products should not be confused with osteoporosis treatment.
Why denosumab offers real hope
The pivotal FREEDOM randomized trial enrolled 7,868 postmenopausal women aged 60 to 90 with osteoporosis. Over three years, compared with placebo:
| Fracture outcome | Placebo | Denosumab | Relative reduction |
|---|---|---|---|
| New radiographic vertebral fracture | 7.2% | 2.3% | 68% |
| Hip fracture | 1.2% | 0.7% | 40% |
| Nonvertebral fracture | 8.0% | 6.5% | 20% |
These are important population-level benefits, but they are not promises for an individual. Absolute benefit depends on baseline fracture risk: someone with a recent vertebral fracture may have more to gain than someone whose fracture risk is low.
Where denosumab fits among osteoporosis treatments
Guidelines do not say that every patient should start with denosumab. The American College of Physicians generally recommends bisphosphonates as initial drug treatment for primary osteoporosis and suggests denosumab as a second-line option when bisphosphonates are contraindicated or cause adverse effects. The Endocrine Society recognizes denosumab as an alternative initial treatment for postmenopausal women at high fracture risk.
This is not a contradiction. It reflects the need to consider fracture severity, kidney function, gastrointestinal tolerance, adherence, cost, patient preference and the long-term treatment pathway. Patients at very high risk, particularly with recent or multiple vertebral fractures, may need assessment for bone-building therapy rather than simply choosing between a bisphosphonate and denosumab.
Who may be considered for denosumab?
- Postmenopausal women with osteoporosis and high fracture risk
- Men with osteoporosis and high fracture risk
- Selected patients with glucocorticoid-induced osteoporosis
- Selected women receiving aromatase-inhibitor treatment for breast cancer and men receiving androgen-deprivation treatment for prostate cancer who meet treatment criteria
- People who cannot use or tolerate an appropriate bisphosphonate, after individual review
Denosumab is not treatment for ordinary back pain, isolated vitamin D deficiency or a mildly low scan result without a proper fracture-risk assessment.
What should be checked before the first injection?
- Confirm the indication: fracture history, DXA results and overall fracture risk should support treatment.
- Plan continuity: the patient must be able to receive reliable six-monthly doses and have a strategy if denosumab later needs to stop.
- Correct low calcium: pre-existing hypocalcaemia must be corrected. Calcium and vitamin D intake or supplementation should be individualized.
- Assess kidney risk: kidney function and the possibility of chronic kidney disease mineral and bone disorder must be considered.
- Review oral health: active dental disease, poor oral hygiene, dentures and planned extractions or implants may change the dental plan before or during treatment.
- Review pregnancy and medicines: denosumab is contraindicated in pregnancy, and other medicines or illnesses may affect calcium or infection risk.
- Verify the product: in Pakistan, use a DRAP-registered product obtained through an authorized pharmacy or healthcare institution, with appropriate storage and administration.
In January 2024, the U.S. FDA added a boxed warning about severe hypocalcaemia in patients with advanced chronic kidney disease, particularly dialysis patients and those with chronic kidney disease mineral and bone disorder. Hospitalization, life-threatening events and deaths have been reported. No dose adjustment does not mean no kidney-related risk.
Patients with advanced kidney disease require assessment by a clinician with expertise in kidney-related mineral and bone disorders, appropriate laboratory evaluation and close calcium monitoring. Denosumab should never be offered casually to a dialysis patient simply because it is not cleared through the kidneys.
The rule that matters most: do not delay or stop casually
Denosumab’s effect reverses when treatment is not continued on schedule. Unlike a bisphosphonate, it is not a medicine for which a routine “drug holiday” is appropriate. After a missed, delayed or stopped dose, bone turnover can rebound, bone density can fall rapidly and vertebral fractures—including multiple vertebral fractures—can occur.
Before denosumab is started, the clinician and patient should discuss what will happen if treatment must end. Guidelines recommend follow-on antiresorptive treatment—often a bisphosphonate when appropriate—to reduce rebound bone loss. The exact medicine and timing depend on individual risk, kidney function, treatment duration and local availability.
Dental care and osteonecrosis of the jaw
Osteonecrosis of the jaw is uncommon in osteoporosis treatment but is serious. Risk is higher with invasive dental procedures, active dental infection, poor oral health, cancer therapies, steroids and longer antiresorptive exposure. The mouth should be reviewed before treatment, and a dental examination may be appropriate when risk factors are present.
Patients should maintain good oral hygiene, attend routine dental care and tell both the prescribing clinician and dentist about denosumab. Decisions around an extraction or other invasive procedure require individualized discussion; patients should not independently skip a dose because dental work is planned.
Other important risks and side effects
- Low calcium, which can cause tingling, muscle spasms, weakness, confusion, seizures or abnormal heart rhythm
- Back, limb, joint or muscle pain
- Skin reactions and, uncommonly, serious infection
- Rare atypical thigh-bone fracture; new persistent thigh or groin pain deserves assessment
- Rare serious allergic reaction
- Multiple vertebral fractures after unprotected discontinuation
Risk lists should inform—not frighten. The correct comparison is the medicine’s risk versus the patient’s untreated fracture risk and the suitability of other options.
Denosumab in Pakistan: product and supply safeguards
Brand availability, registration and supply can change. Patients should verify the current product through the Drug Regulatory Authority of Pakistan database and obtain it only from an authorized establishment. Cold-chain handling and timely administration matter. A lower price is not a benefit if product authenticity or storage is uncertain.
This review does not endorse a specific manufacturer or brand. It also does not assume that U.S. approval automatically establishes Pakistani registration. The exact product proposed for a patient should be checked at the time of prescribing.
Dr. Fowad’s conclusion
Denosumab deserves a positive place in osteoporosis care because it has strong fracture-reduction evidence and convenient six-month dosing. But convenience can become danger when the treatment is treated as a one-off injection. The best denosumab care is a documented pathway: confirm high fracture risk, address calcium and vitamin D, understand kidney and dental risks, administer on schedule, monitor appropriately and plan the eventual transition before the first dose is given.
Frequently asked questions
How often is denosumab given for osteoporosis?
The osteoporosis regimen is a 60 mg injection administered by a healthcare professional every six months. It should not be delayed, interrupted or stopped without a clinician-directed follow-on plan.
Can denosumab be used in kidney disease?
Kidney disease requires particular caution. Patients with advanced chronic kidney disease, especially dialysis or chronic kidney disease mineral and bone disorder, have a substantially increased risk of severe hypocalcaemia and require expert assessment and monitoring.
Do I need a dental check before denosumab?
Oral health should be reviewed before treatment. A dental examination may be advised when risk factors, active dental disease or planned invasive dental work are present. Good oral hygiene and prompt reporting of jaw symptoms remain important during treatment.
What happens if denosumab is stopped?
Bone turnover can rebound, bone density can fall rapidly and vertebral-fracture risk can rise. Denosumab should not be stopped without a plan for another antiresorptive treatment when appropriate.
Primary sources
- Cummings SR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine. 2009;361:756–765.
- U.S. FDA prescribing information for Prolia (denosumab), revised January 2024.
- FDA Drug Safety Communication: severe hypocalcaemia in advanced chronic kidney disease, 19 January 2024.
- Endocrine Society guideline for postmenopausal osteoporosis, 2019 with 2020 update.
- National Osteoporosis Guideline Group recommendations, updated September 2024.
- American College of Physicians living osteoporosis guideline, 2023 with surveillance through February 2025.
- Drug Regulatory Authority of Pakistan public registered-product database, accessed 30 July 2026.
This independent educational review is not a prescription, product endorsement or guarantee of benefit. It summarizes evidence and safety information available on 30 July 2026. Regulatory status, labels, brands and availability can change. Never start, delay or stop denosumab without an individual medical plan.